Buy
Sell
Share Name Share Symbol Market Type Share ISIN Share Description
Emis Group Plc LSE:EMIS London Ordinary Share GB00B61D1Y04 ORD 1P
  Price Change % Change Share Price Shares Traded Last Trade
  0.00 0.0% 1,878.00 217,826 16:35:11
Bid Price Offer Price High Price Low Price Open Price
1,876.00 1,878.00 1,878.00 1,872.00 1,872.00
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Software & Computer Services 168.23 36.09 46.20 40.6 1,189
Last Trade Time Trade Type Trade Size Trade Price Currency
17:30:46 O 49 1,876.00 GBX

Emis (EMIS) Latest News (13)

More Emis News
Emis Investors    Emis Takeover Rumours

Emis (EMIS) Discussions and Chat

Emis Forums and Chat

Date Time Title Posts
20/1/202308:26EMIS - Healthcare IT775

Add a New Thread

Emis (EMIS) Most Recent Trades

No Trades
Trade Time Trade Price Trade Size Trade Value Trade Type
View all Emis trades in real-time

Emis (EMIS) Top Chat Posts

Top Posts
Posted at 05/2/2023 08:20 by Emis Daily Update
Emis Group Plc is listed in the Software & Computer Services sector of the London Stock Exchange with ticker EMIS. The last closing price for Emis was 1,878p.
Emis Group Plc has a 4 week average price of 1,824p and a 12 week average price of 1,824p.
The 1 year high share price is 1,918p while the 1 year low share price is currently 1,116p.
There are currently 63,311,396 shares in issue and the average daily traded volume is 284,362 shares. The market capitalisation of Emis Group Plc is £1,188,988,016.88.
Posted at 08/11/2022 21:18 by wad collector
The agreed price is 1925p, and closing price yesterday was around 1875p , hence a 50p reward for hanging on until completion.
Posted at 07/11/2022 18:37 by ali47fish
but the current price is much lower- where do you get this only 50p- iam not good with maths so please explain
Posted at 06/11/2022 21:57 by wad collector
Slippage in the timetable;

Listed healthcare software developer EMIS Group, whose products are used across a number of major UK healthcare settings, has said it now expects its £1.24bn takeover to complete early next year.

EMIS Group was established in North Yorkshire in 1987 and specialises in connected healthcare software and systems. Its products are used in primary care, community care, accident and emergency, and community and hospital pharmacies.

The Leeds-based company employs about 1,400 staff, primarily in the UK (1,150) and India (250), and it reported revenues of approximately £168m in 2021.

It was announced in June that Bordeaux UK Holdings II (Bidco), an affiliate of Optum Health Solutions (UK) (Optum UK) and a wholly owned subsidiary of UnitedHealth Group Incorporated (UnitedHealth Group) had reached an agreement with the board of EMIS Group on the terms and conditions of a recommended all cash offer.

The proposed acquisition values the entire issued, and to be issued, ordinary share capital of EMIS at approximately £1.24bn.

In August, EMIS Group shareholders voted to proceed with the takeover, and the secretary of state confirmed that no further action will be taken in relation to the acquisition.

The group has now provided an update to the timetable for completion of the deal.

It said the parties are currently in the process of finalising a Merger Notice with the Competition and Markets Authority (CMA), preliminary to a Phase One investigation of the Acquisition.

As a result, unless the relevant condition is waived by Bidco, EMIS now expects the takeover scheme to become effective in the first quarter of 2023.

Travers Smith is acting as legal adviser to EMIS, with Numis as financial adviser, corporate broker and nominated adviser, and MHP as PR adviser.

Slaughter and May is acting as legal adviser to UnitedHealth Group and Bidco, with Robey Warshaw as financial adviser and FGS Global as PR adviser.

Posted at 28/9/2022 09:28 by tomps2
#EMIS Group H122 presentation & acquisition summary.
Rev +5%
aOp Profit +12%
aEPS +14%

www.piworld.co.uk/company-videos/emis-group-emis-2022-half-year-results-presentation-september-2022/

Posted at 22/8/2022 21:36 by wad collector
The resolution has passed, but the timetable has not changed; the vagueness in the original document remains.
1925p before October or about 1940p with dividend if it is not complete by then.So buy today for 1875p to get about 3% in 2 or 3 months. Missing the opportunities elsewhere in that period.


The Scheme remains subject to the sanction by the Court at the Court Hearing and the satisfaction (or, where applicable, the waiver) of the other Conditions to the Scheme (as set out in the Scheme Document).

Subject to the Scheme receiving the sanction of the Court, the filing of the Court Order with the Registrar of Companies and the satisfaction of or, where applicable, the waiver of the other Conditions, the Scheme is expected to become Effective by the end of 2022.

The expected timetable of principal events for the implementation of the Scheme remains as set out on page 9 of the Scheme Document (as defined below). If any of the key dates and/or times set out in the timetable change, EMIS will give notice of this change by issuing an announcement through a Regulatory Information Service.

Prior to the Scheme becoming Effective, it is intended that applications will be made to the London Stock Exchange for the cancellation of trading of EMIS Shares on AIM. It is intended that on the Effective Date, share certificates in respect of EMIS Shares will cease to be valid and entitlements to EMIS Shares held within the CREST system will be cancelled.

Posted at 31/7/2022 09:10 by ali47fish
i thought we have recieved a timetable for the takeover- when does this become irrevoable unless a nother bid turns up- the share price being below the offer price is unusual never experienced this with orthr companies- cant find the document with the timetable pleas if anyone has got a link, post it
Posted at 20/6/2022 13:23 by wad collector
-- Bidco has agreed that: (a) any Permitted Interim Dividend, being an interim dividend of up to 17.60 pence per EMIS Share and (b) any Permitted Final Dividend, being a final dividend of up to 21.10 pence per EMIS Share, may each be declared and paid to EMIS Shareholders without any reduction in the Consideration.

-- If any Permitted Interim Dividend exceeds 17.60 pence and/or any Permitted Final Dividend exceeds 21.10 pence, Bidco reserves the right to reduce the Consideration by an amount equal to such excess amount.

-- If the Effective Date occurs prior to 7 October 2022, there will be no Permitted Interim Dividend and no equivalent payment will be made to EMIS Shareholders by Bidco. If no Permitted Final Dividend is declared and paid or becomes payable prior to the Effective Date, no equivalent payment will be made to EMIS Shareholders by Bidco.




So if taken over before 7th Oct there will be no dividends. Given that we have been paid the final dividend last month , they have 4 months to avoid an interim divi. Assuming all goes through and no counteroffer.
Sp has risen back this morning to about 1875, so I wonder how much point in holding out for another 50p when the market is depressed and buying opportunities elsewhere?

Posted at 22/3/2022 06:53 by tole
https://citywire.com/funds-insider/news/expert-view-emis-secure-trust-bank-abcam-workspace-and-dwf/Emis: Just what the doctor orderedHealthcare software group EMIS (EMIS) is delivering consistent cashflow and therefore dividends, and its cash pile means it can continue to increase its payout annually, says Hargreaves Lansdown fund manager Steve Clayton.In preliminary results, the AIM-quoted group reported a 6% increase in revenues to £168m and a 10% rise in earnings per share, all of which allowed it to raise its dividend for the 11th year in a row, by 10% to 35.2p per share.After strong gains on the news last week, the shares closed 2.6% higher at £13.32 on Monday.Clayton, who holds Emis in his HL Select UK Income fund, where it makes up 4% of the £149m portfolio, said the stock 'stands in a position of strength' thanks to 89% of its revenues being recurring and a £64m cash pile.'The consistency of Emis's cashflows feeds through to its dividend paying abilities,' he said.'Eleven years of consecutive increases is a strong track record. With the payment well covered and the business performing, we see plenty of potential for that payout to grow further over time.'He added that the cash buffer 'provides further reassurance to the dividend and also offers the prospect of further boosting growth through funding earnings enhancing acquisitions'.Clayton concluded: 'Overall, these results were just what the doctor ordered and the market seems to agree.'
Posted at 21/3/2022 10:19 by tomps2
EMIS Group (EMIS) full year 2021 results presentation

EMIS CEO, Andy Thornburn and CFO, Peter Southbury present the full year 2021 results for the period ended 31 December 2021.

Watch the video here: Https://www.piworld.co.uk/company-videos/emis-emis-full-year-2021-results-presentation/

Or listen to the podcast here: Https://piworld.podbean.com/e/emis-group-emis-full-year-2021-results-presentation/

Posted at 18/3/2022 06:37 by tole
EmisThe perceived safety of highly recurring revenue streams has afforded software as a service (SaaS) companies high market ratings. You might think the healthcare software supplier Emis is one of those, with the shares having outperformed the FTSE All-Share more than three times over during the past three years.But while a forward earnings multiple of 21 might look generous, it is not against what has been on offer over the past three years. Roughly 80 per cent of the group's revenue is recurring as its larger health division sells software to the NHS.Hitting a medium-term goal of an adjusted operating margin of 30 per cent could drive its valuation higher. Progress on that score has been impressive: the margin last year came in at 25.9 per cent, up from 22.1 per cent in 2018, when management set out plans to kick-start revenue growth and improve margins.How might it do that? Cost efficiencies are a starting point, which includes refreshing its existing software systems with new technology. But expanding its enterprise division, which focuses on selling medicine dispensation software to pharmacies and hospitals and partnering with smaller third-party technology providers, is the growth engine for the group. The latter, which involves selling software that integrates with the Emis systems to its NHS and private customers, carries little cost for the group and gives a natural kick to margins.Adjusted operating profit for the enterprise division grew a fifth last year, accounting for 40 per cent of the group total, on the back of a 17 per cent revenue rise. That's bang in line with a target to grow the top line at a double-digit rate each year.Growing market share and offering a broader stable of products to customers are the main avenues for revenue growth there. That included acquiring the training system software provider FourteenFish. Analysts at the house broker Numis raised its earnings forecast for this year by 3 per cent off the back of the deal to 58.8p a share, which is also 6 per cent ahead of last year. Emis deserves more credit from the market.ADVICE BuyWHY Sustained growth in margins could prompt a re-rating in the shares
Emis share price data is direct from the London Stock Exchange
Your Recent History
LSE
EMIS
Emis
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

Log in to ADVFN
Register Now

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20230206 03:36:00